Login
$QNRX
$3.69 -$0.01 (0.27%) Live

$QNRX 8-K SEC Filings

Filed On Filing
12 Nov 2026 8-K: Submission of Matters to a Vote of Security Holders

Quoin Pharmaceuticals Ltd. (“we,” “us,” or the “Company”) held a Special General Meeting of Shareholders (the “Special Meeting”) on November 12, 2026. During the Special Meeting, shareholders were asked to consider and vote upon two prop...

06 Nov 2026 8-K: Results of Operations and Financial Condition

– Reports Positive Interim Data from Ongoing Phase 2/3 Study of QRX003 in Netherton Syndrome; Primary and Key Secondary Endpoints Achieved Statistical Significance Versus Pre-Specified Alpha-Adjusted Target

04 Nov 2026 8-K: Entry into a Material Definitive Agreement

Quoin Pharmaceuticals Ltd., a company organized under the laws of Israel (the “Company”), confirms its agreement (this “Agreement”) with Leerink Partners LLC (the “Agent”), as follows:

20 Oct 2026 8-K: Regulation FD Disclosure; Other Events

Quoin Pharmaceuticals Announces Publication of Peer-Reviewed Paper on QRX003 for Netherton Syndrome in Dermatology and Therapy

14 Oct 2026 8-K: Regulation FD Disclosure; Other Events

Quoin Pharmaceuticals Announces European Medicines Agency (EMA) Grants Orphan Drug Designation for QRX003 for the Treatment of Peeling Skin Syndrome

22 Sep 2026 8-K: Regulation FD Disclosure; Other Events

First-Ever Fast Track Designation Granted for a Peeling Skin Syndrome Therapy

10 Sep 2026 8-K: Regulation FD Disclosure; Other Events

FDA Previously Granted RPD Designation for QRX003 in Netherton Syndrome

28 Aug 2026 8-K: Entry into a Material Definitive Agreement; Unregistered Sales of Equity Securities +2 more

This SECURITIES PURCHASE AGREEMENT (this “Agreement”) is dated as of August 27, 2026, by and among Quoin Pharmaceuticals Ltd., a company organized under the laws of Israel (the “Company”), and each of the entities listed on Exhibit A att...

20 Aug 2026 8-K: Departure/Election of Directors or Officers; Compensation; Submission of Matters to a Vote of Security Holders +1 more

Quoin Pharmaceuticals Ltd. (“we,” “us,” or the “Company”) held its 2026 Annual General Meeting of Shareholders (the “Annual Meeting”) on August 20, 2026. At the Annual Meeting, shareholders approved changes to the matching contributions ...

14 Aug 2026 8-K: Results of Operations and Financial Condition

– Receives FDA Conditional Approval of QYLEKI™ as the Proposed Brand Name for QRX003 for Netherton Syndrome

23 Jun 2026 8-K: Regulation FD Disclosure; Other Events

Quoin Pharmaceuticals Receives FDA Conditional Approval of QYLEKI™ as the Proposed Brand Name for QRX003 for Netherton Syndrome

04 Jun 2026 8-K: Regulation FD Disclosure; Other Events

-Designation provides regulatory and development incentives in Japan, including up to 10 years of market exclusivity upon approval-

07 May 2026 8-K: Results of Operations and Financial Condition

– Filed Breakthrough Medicine Designation Application with Saudi FDA for QRX003 in Netherton Syndrome

26 Mar 2026 8-K: Results of Operations and Financial Condition

– Closes Private Placement Financing of Up to $104.5 Million

11 Mar 2026 8-K: Regulation FD Disclosure; Other Events

— Fast Track Designation facilitates development and expedites regulatory review of therapies addressing serious conditions with significant unmet medical need —

20 Jan 2026 8-K: Regulation FD Disclosure; Other Events

Quoin Pharmaceuticals Files Breakthrough Medicine Designation Application in Saudi Arabia for QRX003 in Netherton Syndrome

17 Nov 2025 8-K: Departure/Election of Directors or Officers; Compensation

This Grant Notification Letter (this “Agreement”) evidences a non-qualified stock option granted by Quoin Pharmaceuticals Ltd. (the “Company”) to the individual named above (the “Optionee”), pursuant to and subject to the terms of the Qu...

12 Nov 2025 8-K: Regulation FD Disclosure; Other Events

Quoin Pharmaceuticals Announces Achievement of Topical Rapamycin Target Loadings for Two Proprietary Delivery Technologies

06 Nov 2025 8-K: Results of Operations and Financial Condition

- Private Placement Financing of Up to $105.3 Million Closed in October 2025 to Fund Operations and R&D

21 Oct 2025 8-K: Regulation FD Disclosure; Other Events

Upon Approval of NDA Quoin Will Receive Seven Years Marketing Exclusivity for QRX003 in the US

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Premium Feature

This feature requires a premium subscription to unlock unlimited historical data and advanced analysis tools.

Premium includes:

  • Unlimited historical financial data
  • Advanced analytics and insights
  • Priority support